Rheumnow Podcast

Jaksot

• 
  Obesity & Inflammation: Understanding the Impact on Rheumatic Disease 16.09.2026 1t 1min

  Explore the complex relationship between obesity, inflammation, and rheumatic disease—and how excess adiposity may influence disease development, severity, treatment response, and patient outcomes. In this expert-led discussion, leading clinicians and researchers examine how obesity can accelerate inflammatory and autoimmune rheumatic disease through metabolic, biomechanical, and immunologic pathways. The panel explores the biology of adipose tissue and its role in systemic inflammation, including how obesity affects disease risk and progression, response to rheumatologic therapies, and the potential for weight loss and other interventions to reduce inflammation and improve clinical outcomes. Expert Faculty:• Juliana Simonetti, MD• Lihi Eder, MD, PhD• Naveed Sattar, MD, PhD• Lee Kaplan, MD, PhD• Jack Cush, MD — Moderator
• 
  A Day of Infamy (9.11.2026) 11.09.2026 27min

  Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis.
• 
  Obesity Journal Club 09.09.2026 1t 1min

  The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Authors of the papers and experts will discuss the results of these trials, discuss how we consider obesity as both a comorbidity and part of the disease course, and share practical strategies for addressing obesity in everyday rheumatology practice.Speakers: Dr. Philip Mease Dr. Tom Appleton Dr. Jack Cush (moderator)
• 
  Treating Obesity is Disease-Modifying (9.4.2026) 04.09.2026 25min

  Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control.
• 
  A Day in the Life of a Rheumatology APP: A Focus on Interstitial Lung Disease” (hosted by Amanda Mixon, PA-C) 31.08.2026 28min

  Join Amanda Mixon, PA-C, for a practical look at the role of the rheumatology advanced practice provider (APP) in recognizing and managing interstitial lung disease (ILD). Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
• 
  DERM on RheumNow PODCAST (August 2026) 28.08.2026 12min

  The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes:Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0 POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0 MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs 39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower mortality jSSc (7.7% vs. 20.4%) https://t.co/vflarmwSyv Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ 3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo
• 
  NME: New Molecular Entities (8.28.2026) 28.08.2026 30min

  Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
• 
  Label update: Structural damage progression in active PsA 24.08.2026 16min

  Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update. Sponsored by Johnson & Johnson Medical Affairs
• 
  Rheum Scholarship (8.21.2026) 21.08.2026 26min

  Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.
• 
  Doubting RS3PE (8.14.2026) 14.08.2026 31min

  Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
• 
  Mentshlichkeit (8.7.2026) 07.08.2026 22min

  Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com
• 
  A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12 03.08.2026 25min

  Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact
• 
  TU: Systemic Burden of Gout Part 2 (24 plus) 31.07.2026 29min

  Dr. Jack Cush Obesity & Gout Dr. Tony Merriman Genome-Wide Association Studies in Gout Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease Dr. Mark Fisher Gout & Mortality  
• 
  Methotrexate Safety Tips (7.31.2026) 31.07.2026 20min

  Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
• 
  Gout Lessons from the Clinic Part 3 30.07.2026 28min

  Dr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout Dr. Jack Cush QD319 A Watched Tophus Never Resolves  Dr. Eric Dein QD316: Addressing Severe Gout Flares  Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout 
• 
  DERM on RheumNow (July 2026) 29.07.2026 10min

  The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com.Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026
• 
  New, Advanced Therapies in Gout 29.07.2026 1t 1min

  New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)
• 
  Systemic Burden of Gout Part 1 29.07.2026 34min

  Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout  Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?
• 
  Better Gout Management 29.07.2026 19min

  Dr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity
• 
  Gout Advice & Tips 29.07.2026 24min

  Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome  Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout